After the use of fatty acid inhibitor etomoxir (ETO), it can significantly inhibit the growth of CPS1 deficient tumor cells, and improve the sensitivity of tumor cells to sorafenib (Wu et al., 2021). This evidence concerns the gene CPS1 and neoplasm.